ŞU** B*****

Dr. ŞU** B*****


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Annals of Neurosciences
Verified
Journal Article
Open access
ŞBŞU** B*****
ŞU** B*****
HUHasan Armağan Uysal
Hasan Armağan Uysal
SBSinan Bilgin
Sinan Bilgin
EYEmiş Cansu Yaka
Emiş Cansu Yaka
ÖKÖzge Yılmaz Küsbeci
Özge Yılmaz Küsbeci
UŞUfuk Şener
Ufuk Şener
Background: The retina is affected by Parkinson’s disease (PD). Purpose: We aimed to assess the anatomical and vascular deterioration of the retina in PD. Methods: Sixty-six patients with PD and 66 healthy volunteers were evaluated in this study. Choriocapillaris vessel density (CCVD), superficial vascular density (SVD), deep vascular densities (DVD), central macular thickness (CMT), retinal nerve fibre layer (RNFL), ganglionic cell layer (GCL), and choroidal thickness (CT) were assessed. Results: RNFL, GCL, CMT, and CT were thinner than in HC, and also the differences between the groups were statistically significant ( P < .05). SVD and DVD were not statistically different between the groups ( P > .05). There was a decrease in vascular density in all quadrants of the choriocapillary layer. The decrease in vascular density was statistically significant in the nasal, inferior and central quadrants ( P < .05). Conclusion: These results supported vascular thinning in the choroidal layer. Also showed that vascular and neural layers were affected together. It could help clinicians in the follow-up of Parkinson’s patients.

1 January 2016 in The Anatolian Journal of General Medical Research
Verified
Journal Article
Closed access
FUFeray Güleç Uyaroğlu
Feray Güleç Uyaroğlu
ŞBŞU** B*****
ŞU** B*****
EKElif Hacer Keleş
Elif Hacer Keleş
YZYaşar Zorlu
Yaşar Zorlu


30 March 2023 in İzmir Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
IAİrem Fatma Aşan
İrem Fatma Aşan
ŞBŞU** B*****
ŞU** B*****
HTHande Turan
Hande Turan
UŞUfuk Şener
Ufuk Şener
Aim: Varicella zoster virus (VZV) infections can cause various neurological syndromes during primary infection or reactivation periods. We report two rare neurological complications of VZV, acute longitudinally extensive myelitis and acute motor axonal neuropathy due to primary chickenpox infection that occurred concomitantly. Case: A 76-year-old female patient presented with skin lesions consistent with chickenpox all over the body and walking difficulty ten days ago. Neurological examination revealed paraparesis and areflexia. Spinal cord magnetic resonance imaging revealed a long-segment transverse myelitis lesion involving the lower cervical and thoracic levels. Elevated protein and the presence of VZV DNA were detected in the cerebrospinal fluid, and VZV IgM was detected in the serum. Two days later, the patient's weakness in her legs increased. Electromyography showed signs of acute axonal motor polyneuropathy. The patient was treated with intravenous immunoglobulin after high-dose steroid and antiviral therapy. Partial recovery was observed. Conclusion: Transverse myelitis and Guillain Barré syndrome are rare complications of VZV infection. Our case is first case where these two neorological conditions related to VZV were seen in the same patient.

29 April 2026 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
OAOzlem Yagiz Agayarov
Ozlem Yagiz Agayarov
IAI. B. Arslan
I. B. Arslan
ATA. Coban Taskin
A. Coban Taskin
EBE. Boluk
E. Boluk
ŞBŞU** B*****
ŞU** B*****
ICI. Cukurova
I. Cukurova

26 August 2024 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
ŞBŞU** B*****
ŞU** B*****
KOKaan Tugberk Ozdemir
Kaan Tugberk Ozdemir
EYEmiş Cansu Yaka
Emiş Cansu Yaka
ÖDÖmer Demir
Ömer Demir
HAHuriye Aydın
Huriye Aydın
UŞUfuk Şener
Ufuk Şener
Objectives: The aim of the study is to assess the prevalence and clinical features of headache in patients treated with botulinum toxin for blepharospasm and hemifacial spasm. In addition, our secondary aim was to identify potential factors influencing the development of these headaches Methods: A total of 70 patients who were treated with on a botulinum toxin A for dystonia treatment in our clinic between January 2023 and March 2023 were retrospectively screened, and the clinical and demographic characteristics of the patients who reported headache complaints after the last botulinum toxin treatment were examined. Results: Headache was reported in 8 (%11.4) of the 70 patients included in the study. Of the 8 patients who reported headaches, 6 (%75) had the onset of the complaint within the first 24 hours. There was no significant correlation between headache occurrence and factors like age, gender, diagnosis, botulinum toxin dosage, application site, comorbid diseases, or hypertension. However, a statistically significant link was observed between the intensity of pain experienced during treatment and the frequency of headaches after the treatment Conclusions: Botulinum toxin treatment can lead to short-term headaches in some patients, starting early after the procedure. The significant link between the frequency of these headaches and the pain experienced during injection highlights the need to examine factors like the volume and dilution rate of the toxin, the solvent used, treatment area, treatment purpose, patient characteristics, and the physician's technique. It is important to study these aspects by comparing them across a large patient group and control subjects.